ZBIO — Zenas BioPharma, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1953926 ·
Last close
$27.75
Market Cap
$1.88B
52W High
$44.60
52W Low
$13.50
ADV30
512,515
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 10,000,000 — -75,909,000 -108,923,000 675,216,000 177,778,000 462,908,000
Jun 2026 1,000,000 — -77,659,000 -111,456,000 701,690,000 196,577,000 454,593,000
Mar 2026 0 — -77,350,000 -80,987,000 747,682,000 500,224,000 411,853,000
Dec 2025 0 — -71,312,000 -240,442,000 383,640,000 110,641,000 141,496,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-242,831,000
Investing CF
$-368,666,000
Financing CF
$673,591,000
CapEx
$-65,002,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.42
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,066,494,000
Inventory
—
Receivables
—
ST Investments
$446,549,000
EBIT TTM
$-503,466,000
Pretax Income TTM
$-541,539,000
Interest Exp TTM
$29,832,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,000,000
EBITDA
$-273,870,016
Free Cash Flow
$-211,391,632
Enterprise Value
$1,509,664,512
Total Cash
$643,126,016
Total Debt
$297,860,992
Shares Out
67,817,793
Trailing EPS
$-10.08
Book Value
$4.44
ROE
-199.0%
ROA
-34.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 10,000,000 -211,385,000 -377,737,000 383,640,000 141,496,000 242,144,000 -172,333,000
Dec 2024 5,000,000 -163,888,000 -156,988,000 369,968,000 57,510,000 312,458,000 -119,674,000
Dec 2023 50,000,000 -27,147,000 -37,124,000 68,180,000 293,901,000 -225,721,000 -30,529,000
Dec 2022 0 -75,199,000 -119,282,000 74,579,000 266,865,000 -192,286,000 -65,652,000

TTM Snapshot

Revenues TTM
$4,018,000
NetIncome TTM
$-484,384,000
OpCashFlow TTM
—
Assets (Latest)
$701,690,000
Forward EPS
$-4.66

Max Pain — expiry 2027-01-15

max pain strike: $20.00 · spot: $26.42 · call oi: 1,026 · put oi: 2
Expected Move to 2027-01-15: ±$11.43 (43.26%) — implied range $14.99 – $37.85 · ATM straddle on $25.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
HMDCF HUTCHMED (China) Ltd $1.88B $2.16 —
VERA Vera Therapeutics, Inc. $1.89B $26.20 —
SEPN Septerna, Inc. $1.90B $40.02 —
TRVI Trevi Therapeutics, Inc. $1.93B $13.51 —
ETON Eton Pharmaceuticals, Inc. $1.84B $63.65 —

News headlines (Yahoo Finance, 1h cache)

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-18 21:15 · Yahoo
Zenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related Disease
2026-11-17 12:00 · Yahoo
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
2026-11-09 12:00 · Yahoo
Zenas BioPharma (ZBIO) After Third Quarter Losses Still Carries An Undervalued Narrative
2026-11-07 06:11 · Yahoo
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 12:00 · Yahoo
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
2026-10-30 15:14 · Yahoo
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
2026-10-23 12:55 · Yahoo
Zenas BioPharma Stock Gains Attention After Long Term Trial Data
2026-10-21 00:17 · Yahoo
Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release
2026-10-13 08:18 · Yahoo
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
2026-10-12 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.